These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Comparative effects of lovastatin and chenodeoxycholic acid on plasma cholestanol levels and abnormal bile acid metabolism in cerebrotendinous xanthomatosis. Salen G; Batta AK; Tint GS; Shefer S Metabolism; 1994 Aug; 43(8):1018-22. PubMed ID: 8052141 [TBL] [Abstract][Full Text] [Related]
29. Malar rash and hand tremor in early symptoms of cerebrotendinous xanthomatosis and the effect of chenodeoxycholic acid on them. Yılmaz BK; Çelik H J Clin Lipidol; 2024; 18(3):e452-e464. PubMed ID: 38461119 [TBL] [Abstract][Full Text] [Related]
30. Neurological outcome in cerebrotendinous xanthomatosis treated with chenodeoxycholic acid: early versus late diagnosis. Yahalom G; Tsabari R; Molshatzki N; Ephraty L; Cohen H; Hassin-Baer S Clin Neuropharmacol; 2013; 36(3):78-83. PubMed ID: 23673909 [TBL] [Abstract][Full Text] [Related]
32. Treatment of cerebrotendinous xanthomatosis: effects of chenodeoxycholic acid, pravastatin, and combined use. Kuriyama M; Tokimura Y; Fujiyama J; Utatsu Y; Osame M J Neurol Sci; 1994 Aug; 125(1):22-8. PubMed ID: 7964884 [TBL] [Abstract][Full Text] [Related]
33. Differing clinical features between Japanese siblings with cerebrotendinous xanthomatosis with a novel compound heterozygous CYP27A1 mutation: a case report. Koyama S; Okabe Y; Suzuki Y; Igari R; Sato H; Iseki C; Tanji K; Suzuki K; Ohta Y BMC Neurol; 2022 May; 22(1):193. PubMed ID: 35614401 [TBL] [Abstract][Full Text] [Related]
35. Using fiber tractography and diffusion kurtosis imaging to evaluate neuroimaging changes in patients with cerebrotendinous xanthomatosis after stopping chenodeoxycholic acid treatment for three years. Lee JJ; Chang CC; Chang WN Biomed J; 2022 Oct; 45(5):814-820. PubMed ID: 34543727 [TBL] [Abstract][Full Text] [Related]
36. Could steroids mask the diagnosis of cerebrotendinous xanthomatosis? Siman-Tov T; Meiner V; Gadoth N J Neurol Sci; 2006 Apr; 243(1-2):83-6. PubMed ID: 16445943 [TBL] [Abstract][Full Text] [Related]
37. Genetically and clinically confirmed atypical cerebrotendinous xanthomatosis with normal cholestanol and marked elevations of bile acid precursors and bile alcohols. DeBarber AE; Schaefer EJ; Do J; Ray JW; Larson A; Redder S; Fowler M; Duell PB J Clin Lipidol; 2024; 18(3):e465-e476. PubMed ID: 38637260 [TBL] [Abstract][Full Text] [Related]
38. [Usefulness of cholestanol levels in the diagnosis and follow-up of patients with cerebrotendinous xanthomatosis]. Pilo de la Fuente B; Sobrido MJ; Girós M; Pozo L; Lustres M; Barrero F; Macarrón J; Díaz M; Jiménez-Escrig A Neurologia; 2011 Sep; 26(7):397-404. PubMed ID: 21345536 [TBL] [Abstract][Full Text] [Related]
39. The wide spectrum of cerebrotendinous xanthomatosis: Case report of a rare but treatable disease. Rosafio F; Cavallieri F; Guaraldi P; Taroni F; Nichelli PF; Mandrioli J Clin Neurol Neurosurg; 2016 Apr; 143():1-3. PubMed ID: 26874936 [TBL] [Abstract][Full Text] [Related]
40. Elevated cholesterol precursors other than cholestanol can also be a hallmark for CTX. de Sain-van der Velden MG; Verrips A; Prinsen BH; de Barse M; Berger R; Visser G J Inherit Metab Dis; 2008 Dec; 31 Suppl 2():S387-93. PubMed ID: 18949577 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]